Emerging Biotech Grant Program - FAQs

The grant is open to all biotech companies in the following countries:

• UK, Ireland, Belgium, France, The Netherlands, Germany, Austria, Switzerland, Denmark, Sweden, Norway, Finland, and Spain.

All applications will be judged based on:

• (i) the scientific and societal merit of the therapy being developed, and
• (ii) process challenges and expertise gaps associated with the development of the therapy

We take confidentiality very seriously. Applicants’ submissions are protected through the Official Rules. Please contact your local representative with any questions or email us (mark.rogers@merckgroup.com)

No, you continue to own your intellectual property. Section 11 of the Official Rules states that Merck KGaA, Darmstadt, Germany can use the information provided by the Participant, but does not own it. Merck KGaA, Darmstadt, Germany uses the application information for internal processes to improve understanding of our customers’ needs.

Projects funded by the European Commission are eligible per the Official Rules.

Visit www.merkmillipore.com/EBGrant for submission guidelines and official rules.

Per the Official Rules, the 2016 grant winners will receive Merck KGaA, Darmstadt, Germany products and services. There are a total of 4 awards:

• 1st Prize €100k
• 2nd Prize €50k
• 3rd Prize €25k
• 4th Prize €25k

Which can be spent on:

• Merck KGaA, Darmstadt, Germany Process Solutions products and services, and process development support.

Grant Applications received on or before 30th June 2016, will be entered into a separate competition to win an iPad® tablet. One winner will be selected randomly from applications received. The winner will be announced on or around 15th November 2016. Please refer to the Official Rules for more information.

Midnight on 30th September 2016.

On or around 1st November 2016

On or around 15th November 2016

15th April 2016